Table S1.
Characteristics of primary AML cells used in this study
| Sample | Sex/age, y | Source | FAB | Karyotype | Molecular aberrations | IL1RAP expression |
| AML1 | M/40 | PB | ND* | 46,XY | FLT3-ITD−/FLT3-TKD−, NPM1+ | High |
| AML2 | F/46 | PB | M2 | 46,XX | FLT3-ITD+/FLT3-TKD−, NMP1+ | High |
| AML3 | F/71 | BM | M5 | 46,XX | FLT3−, NPM1− | Intermediate |
| AML4 | F/65 | PB | M4/M5 | 47,XX,+8[21]/46,XX[4] | FLT3-ITD−/FLT3-TKD−, NPM1+ | High |
| AML5 | F/67 | BM | ND* | 46,XX | FLT3+ | High |
| AML6 | M/52 | BM | ND* | 46,XY,t(9;11) | FLT3−, NPM1− | Intermediate |
| AML7 | F/45 | BM | M2 | 46,XX | FLT3-ITD+/FLT3-TKD−, NPM1+ | High |
| AML8 | F/74 | BM | ND* | 46,XX | FLT3-ITD−/FLT3-TKD−, NPM1− | Intermediate |
| AML9 | F/72 | BM | M4 | 46,XX | FLT3-ITD−/FLT3-TKD+ | Intermediate |
IL1RAP expression was determined by flow cytometry as described (9). F, female; FAB, French–American–British classification; M, male; ND, not determined.